financetom
Business
financetom
/
Business
/
Why Hess Midstream Stock Is Trading Lower
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Hess Midstream Stock Is Trading Lower
May 30, 2024 7:24 AM

Hess Midstream LP ( HESM ) shares are trading lower by 3.83% to $34.44 during Thursday’s session after the company announced a 10 million share offering by a selling shareholder.

The public offering aims to generate $343 million in gross proceeds. The underwriter, J.P. Morgan, has a 30-day option to buy up to 1.5 million additional shares. Hess Midstream ( HESM ) will not receive any proceeds from this sale.

The offering is set to close on May 31, pending customary conditions. The shares will be sold on the NYSE, over-the-counter, or through negotiated transactions at market or negotiated prices.

See Also: Kohl’s Q1 Earnings: Revenue And Profit Miss, Outlook Cut, Stock Tumbles

How To Buy HESM Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Hess Midstream’s case, it is in the Energy sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, HESM has a 52-week high of $36.84 and a 52-week low of $27.11.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump
iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump
May 10, 2024
09:40 AM EDT, 05/10/2024 (MT Newswires) -- iTeos Therapeutics ( ITOS ) reported a Q1 net loss Friday of $1.07 per diluted share, widening from a net loss of $0.44 per share a year earlier. Four analysts polled by Capital IQ expected a loss of $1.37. The clinical-stage company said it ended Q1 with $595 million in cash, cash equivalents,...
Factbox-Chinese EV makers set sights on European production
Factbox-Chinese EV makers set sights on European production
May 10, 2024
(Reuters) -Some Chinese carmakers are looking to set up manufacturing and assembly plants in Europe as they aim to ramp up sales of lower-cost cars in the region to rival their European competitors amid slowing demand at home. European imports of Chinese-made electric vehicles (EVs) have soared in recent years, raising concerns among domestic EV producers that they could suffer...
MediaAlpha Closes $144.2 Million Secondary Offering
MediaAlpha Closes $144.2 Million Secondary Offering
May 10, 2024
09:30 AM EDT, 05/10/2024 (MT Newswires) -- MediaAlpha ( MAX ) announced Friday the closing of a secondary offering of nearly 7.6 million class A common shares previously owned by affiliates of White Mountains Insurance Group ( WTM ) and Insignia Capital Group at $19 apiece, generating $144.2 million in gross proceeds for the selling shareholders. Underwriters for the deal...
Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise
Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise
May 10, 2024
09:28 AM EDT, 05/10/2024 (MT Newswires) -- Rocket Pharmaceuticals ( RCKT ) said Friday that longer-term data on its experimental gene therapies to treat patients with rare blood disorders showed sustained safety and efficacy. Kresladi, a treatment for severe leukocyte adhesion deficiency, showed 100% stem cell transplantation-free survival with significant reductions in infection-related hospitalizations following engraftment, the company said. Data...
Copyright 2023-2026 - www.financetom.com All Rights Reserved